211 related articles for article (PubMed ID: 15330257)
41. TIR domain-containing adaptors define the specificity of TLR signaling.
Yamamoto M; Takeda K; Akira S
Mol Immunol; 2004 Feb; 40(12):861-8. PubMed ID: 14698224
[TBL] [Abstract][Full Text] [Related]
42. Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors.
O'Neill LA; Dunne A; Edjeback M; Gray P; Jefferies C; Wietek C
J Endotoxin Res; 2003; 9(1):55-9. PubMed ID: 12691620
[TBL] [Abstract][Full Text] [Related]
43. Frontline: control of Anaplasma phagocytophilum, an obligate intracellular pathogen, in the absence of inducible nitric oxide synthase, phagocyte NADPH oxidase, tumor necrosis factor, Toll-like receptor (TLR)2 and TLR4, or the TLR adaptor molecule MyD88.
von Loewenich FD; Scorpio DG; Reischl U; Dumler JS; Bogdan C
Eur J Immunol; 2004 Jul; 34(7):1789-97. PubMed ID: 15214027
[TBL] [Abstract][Full Text] [Related]
44. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6.
Häcker H; Vabulas RM; Takeuchi O; Hoshino K; Akira S; Wagner H
J Exp Med; 2000 Aug; 192(4):595-600. PubMed ID: 10952730
[TBL] [Abstract][Full Text] [Related]
45. Modulation of Toll-interleukin 1 receptor mediated signaling.
Li X; Qin J
J Mol Med (Berl); 2005 Apr; 83(4):258-66. PubMed ID: 15662540
[TBL] [Abstract][Full Text] [Related]
46. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62.
Goodridge HS; Marshall FA; Else KJ; Houston KM; Egan C; Al-Riyami L; Liew FY; Harnett W; Harnett MM
J Immunol; 2005 Jan; 174(1):284-93. PubMed ID: 15611251
[TBL] [Abstract][Full Text] [Related]
47. Cell activation by Porphyromonas gingivalis lipid A molecule through Toll-like receptor 4- and myeloid differentiation factor 88-dependent signaling pathway.
Ogawa T; Asai Y; Hashimoto M; Takeuchi O; Kurita T; Yoshikai Y; Miyake K; Akira S
Int Immunol; 2002 Nov; 14(11):1325-32. PubMed ID: 12407023
[TBL] [Abstract][Full Text] [Related]
48. Toll-like receptors and their role in the development of autoimmune diseases.
Toubi E; Shoenfeld Y
Autoimmunity; 2004 May; 37(3):183-8. PubMed ID: 15497450
[TBL] [Abstract][Full Text] [Related]
49. TLR2 as an essential molecule for protective immunity against Toxoplasma gondii infection.
Mun HS; Aosai F; Norose K; Chen M; Piao LX; Takeuchi O; Akira S; Ishikura H; Yano A
Int Immunol; 2003 Sep; 15(9):1081-7. PubMed ID: 12917260
[TBL] [Abstract][Full Text] [Related]
50. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling.
Gohda J; Matsumura T; Inoue J
J Immunol; 2004 Sep; 173(5):2913-7. PubMed ID: 15322147
[TBL] [Abstract][Full Text] [Related]
51. Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88.
Campos MA; Closel M; Valente EP; Cardoso JE; Akira S; Alvarez-Leite JI; Ropert C; Gazzinelli RT
J Immunol; 2004 Feb; 172(3):1711-8. PubMed ID: 14734753
[TBL] [Abstract][Full Text] [Related]
52. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration.
Seki E; Tsutsui H; Iimuro Y; Naka T; Son G; Akira S; Kishimoto T; Nakanishi K; Fujimoto J
Hepatology; 2005 Mar; 41(3):443-50. PubMed ID: 15723296
[TBL] [Abstract][Full Text] [Related]
53. Suppression of allergic reaction by lambda-carrageenan: toll-like receptor 4/MyD88-dependent and -independent modulation of immunity.
Tsuji RF; Hoshino K; Noro Y; Tsuji NM; Kurokawa T; Masuda T; Akira S; Nowak B
Clin Exp Allergy; 2003 Feb; 33(2):249-58. PubMed ID: 12580919
[TBL] [Abstract][Full Text] [Related]
54. Toll-like receptors as adjuvant receptors.
Kaisho T; Akira S
Biochim Biophys Acta; 2002 Feb; 1589(1):1-13. PubMed ID: 11909637
[TBL] [Abstract][Full Text] [Related]
55. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence.
Stack J; Haga IR; Schröder M; Bartlett NW; Maloney G; Reading PC; Fitzgerald KA; Smith GL; Bowie AG
J Exp Med; 2005 Mar; 201(6):1007-18. PubMed ID: 15767367
[TBL] [Abstract][Full Text] [Related]
56. Unresponsiveness of MyD88-deficient mice to endotoxin.
Kawai T; Adachi O; Ogawa T; Takeda K; Akira S
Immunity; 1999 Jul; 11(1):115-22. PubMed ID: 10435584
[TBL] [Abstract][Full Text] [Related]
57. Toll-like receptor-mediated tyrosine phosphorylation of paxillin via MyD88-dependent and -independent pathways.
Hazeki K; Masuda N; Funami K; Sukenobu N; Matsumoto M; Akira S; Takeda K; Seya T; Hazeki O
Eur J Immunol; 2003 Mar; 33(3):740-7. PubMed ID: 12616494
[TBL] [Abstract][Full Text] [Related]
58. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta.
Seki E; Tsutsui H; Nakano H; Tsuji N; Hoshino K; Adachi O; Adachi K; Futatsugi S; Kuida K; Takeuchi O; Okamura H; Fujimoto J; Akira S; Nakanishi K
J Immunol; 2001 Feb; 166(4):2651-7. PubMed ID: 11160328
[TBL] [Abstract][Full Text] [Related]
59. Genetic approaches to the study of Toll-like receptor function.
Takeuchi O; Akira S
Microbes Infect; 2002 Jul; 4(9):887-95. PubMed ID: 12106781
[TBL] [Abstract][Full Text] [Related]
60. Toll IL-1 receptors differ in their ability to promote the stabilization of adenosine and uridine-rich elements containing mRNA.
Datta S; Novotny M; Li X; Tebo J; Hamilton TA
J Immunol; 2004 Aug; 173(4):2755-61. PubMed ID: 15294994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
